DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Furnes, B.
Right arrow Articles by Schlenk, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Furnes, B.
Right arrow Articles by Schlenk, D.

Vol. 31, Issue 2, 187-193, February 2003

Identification of Novel Variants of the Flavin-Containing Monooxygenase Gene Family in African Americans

Bjarte Furnes, Jinong Feng, Steve S. Sommer, and Daniel Schlenk

Environmental Toxicology Program, University of California, Riverside, California (B.F., D.S.); and Department of Molecular Genetics, City of Hope National Medical Center, Duarte, California (J.F., S.S.)

Sequence polymorphisms in enzymes involved in drug metabolism have been widely implicated in the differences observed in the sensitivity to various xenobiotics. The flavin-containing monooxygenase (FMO) gene family in humans catalyzes the monooxygenation of numerous N-, P- and S-containing drugs, pesticides, and environmental toxicants. Six genes (FMO1-6) have been identified so far, but the major alleles of FMO2 and FMO6 encode nonfunctional proteins due to a nonsense mutation and splice-site abnormalities, respectively. Data on structural variants exist for human FMO2 and 3, whereas very little is known about the other FMO genes. FMO1-6 were scanned in 50 individuals of African-American descent using the method, detection of virtually all mutations-single-strand conformational polymorphism. A total of 49 sequence variants were identified in a total 1.35 megabases of scanned sequence, of which 29 were variants affecting protein structure or expression. Some of these are expected to affect the activity of the protein, including a nonsense mutation in FMO1 (R502X) and missense mutations in FMO1 (I303T), FMO4 (E339Q), and FMO5 (P457L) that occur in highly conserved amino acids. Additional deleterious substitutions in FMO2 (del337G) and FMO6 (Q105X) were also identified. Multiple structural variants in the FMO gene family were observed in this African-American sample. Some of the substitutions identified in this study might be useful markers in future association studies assessing sensitivity to environmental toxicants and common disease.

Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
T. Borbas, J. Zhang, M. A. Cerny, I. Liko, and J. R. Cashman
Investigation of Structure and Function of a Catalytically Efficient Variant of the Human Flavin-Containing Monooxygenase Form 3
Drug Metab. Dispos., December 1, 2006; 34(12): 1995 - 2002.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Eswaramoorthy, J. B. Bonanno, S. K. Burley, and S. Swaminathan
Mechanism of action of a flavin-containing monooxygenase
PNAS, June 27, 2006; 103(26): 9832 - 9837.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. K. Krueger, L. K. Siddens, S. R. Martin, Z. Yu, C. B. Pereira, E. T. Cabacungan, R. N. Hines, K. G. Ardlie, J. L. Raucy, and D. E. Williams
DIFFERENCES IN FMO2*1 ALLELIC FREQUENCY BETWEEN HISPANICS OF PUERTO RICAN AND MEXICAN DESCENT
Drug Metab. Dispos., December 1, 2004; 32(12): 1337 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
B. Furnes and D. Schlenk
Evaluation of Xenobiotic N- and S-Oxidation by Variant Flavin-Containing Monooxygenase 1 (FMO1) Enzymes
Toxicol. Sci., April 1, 2004; 78(2): 196 - 203.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. N. Hines, Z. Luo, K. A. Hopp, E. T. Cabacungan, S. B. Koukouritaki, and D. G. McCarver
Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6)
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1210 - 1218.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. Lattard, J. Zhang, Q. Tran, B. Furnes, D. Schlenk, and J. R. Cashman
TWO NEW POLYMORPHISMS OF THE FMO3 GENE IN CAUCASIAN AND AFRICAN-AMERICAN POPULATIONS: COMPARATIVE GENETIC AND FUNCTIONAL STUDIES
Drug Metab. Dispos., July 1, 2003; 31(7): 854 - 860.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.